

# Comparison of ActiGraph, Fitbit and Manual Step Count During a Two-Minute Walk Test in People with Multiple Sclerosis: A Pilot Study

V Block, PT, DPTSc (c),<sup>1</sup> A Lizée, MSc,<sup>2</sup> E Crabtree, MD,<sup>2</sup> C Bevan, MD,<sup>2</sup> J Graves, MD, PhD,<sup>2</sup> M Tremblay, MD, PhD,<sup>2</sup> B Nourbakhsh, MD,<sup>2</sup>

A Green, MD, MCR,<sup>2</sup> M Pletcher, MD, MPH,<sup>3</sup> B Cree, MD, PhD, MAS,<sup>2</sup> DD Allen, PT, PhD,<sup>1</sup> JM Gelfand, MD<sup>2</sup>

(1) University of California San Francisco / San Francisco State University: Graduate Program in Physical Therapy; (2) University of California San Francisco: School of Medicine, Clinical Neurology;

(3) University of California, San Francisco: School of Medicine, Epidemiology and Biostatistics

## Background:

- Multiple sclerosis (MS) commonly leads to impairments in gait
- Remote physical activity monitoring in the patient's natural environment has the potential to augment measurement of MS-related disability and disease progression and might have prognostic value.
- Neurological disability may influence the fidelity of step count monitoring

## Objective:

Compare remote physical activity monitoring using commercially available devices in people with MS with a broad range of ambulatory impairments.

## Methods:

### Subjects:

- 61 adults with MS at UCSF MS Center.

### Exclusion criteria:

- Recent clinical relapse ( $\leq 30$  days), physical comorbidities that could contribute to gait impairment and confound results.

### Measures of step count during 2-minute walk (2MW):

- Fitbit Flex<sup>®</sup>
- Research-grade accelerometer (ActiGraph)
- Manual step counting (by a physical therapist)

**Table 1: Participant Demographic Data**

	All	Progressive	Relapsing
<b>N</b>	61	19	42
<b>Age (y)*</b>	50 (14.4)	58.5 (8.4)	46.3 (15.0)
<b>EDSS †</b>	4.0 (0-6.5)	6.0 (3.0-6.5)	2.8 (0-6.0)
<b>DD (y) †</b>	10 (4-21)	15 (8-20)	9 (4-22)

\* Mean (standard deviation); † median (range)

EDSS = Kurtzke Expanded Disability Status Scale; DD = disease duration

**Fitbit Flex<sup>®</sup>**



**ActiGraph GT3X**



**Manual Counting**




## Results:

Bland-Altman plots showed:

- No systematic difference between the number of steps measured by Fitbit vs. manual counts (across the range of step counts).
- ActiGraph measurements tended to under-record actual steps taken at slower gait speeds.
- Interclass correlation coefficients (ICC) comparing total step counts across methods during the 2MW revealed moderate correlations.

**Bland-Altman Plots Comparing the Step Count Measuring Techniques**



**Table 2: Interclass Correlation Coefficients**

Step Count Measures	Fitbit vs. manual	Fitbit vs. ActiGraph	ActiGraph vs. manual
ICC (95% CI)	<b>0.69</b> (0.53 - 0.80)	<b>0.59</b> (0.40 - 0.73)	<b>0.76</b> (0.63 - 0.85)

## Discussion:

- Wrist-worn commercial accelerometers (Fitbit<sup>®</sup> Flex) appear to **provide a valid alternative** to more expensive, research grade accelerometers for determining step count in people with MS, particularly at slower gait speeds.
- Further study is ongoing in the community setting to evaluate associations with longer-term patterns of neurological impairment and gait abnormalities.

**Acknowledgement:** The FITriMS study is a sub-study of the UCSF Health e-Heart study. Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the NIH under Award Number KL2TR000143 (JMG).